Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    10569399 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Conditions: Lung Cancer;   Head and Neck Cancer;   Hearing Loss;   Ototoxicity;   Tinnitus;   Neuropathy
Interventions: Drug: SPI-1005 Low Dose;   Drug: SPI-1005 Middle Dose;   Drug: SPI-1005 High Dose;   Drug: Placebo
2 Completed The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
Conditions: Ototoxicity;   Hearing Loss
Interventions: Drug: Ginkgo Biloba Extract (GBE761);   Drug: Placebo

Indicates status has not been verified in more than two years